Immune Support & Healthy Aging

Thymosin Alpha-1 & Epitalon FDA Regulatory Status
Regulatory Guidance & Legal Compliance for Licensed Practitioners

There are two peptides that mostly dominate clinic conversations in this category: Thymosin Alpha-1 and Epitalon. This page documents where each of them stands as of August 2026, and it opens with a correction, because the category name invites the opposite assumption. Ageing is not an indication FDA recognises. No drug is approved in the United States to treat it, slow it, or extend lifespan. Grouping these peptides under “healthy aging” describes how they are marketed and discussed. It does not describe a regulatory category, and neither substance has been evaluated by FDA for such a use.

How We Work:

Phoenix Meds Inc. is a peptide sourcing coordinator for licensed clinics. We coordinate sourcing where a lawful pathway exists, provide regulatory documentation where it does not, and tell clinics plainly which is which. For the statutory framework, the criteria under sections 503A and 503B, research-use-only labelling and enforcement risk, see how the compounding rules work. This page covers what applies to this category only.

HOW WE SUPPORT CLINICS

Phoenix Meds Regulatory Support Model

This category has a specific trap: both substances carry credentials that look like approval and are not. Our support here is built around separating what a credential actually means from what a supplier says it means.

Foreign Approval Is Not US Approval

Thymosin Alpha-1 is marketed under the name Zadaxin in a number of countries outside the United States. That has no bearing on what a US pharmacy may compound, and it satisfies none of the statutory conditions. We separate the two questions on every quote we review.

Designation Is Not Authorisation

Orphan drug designation, nomination for a bulks list, and an advisory committee recommendation are three different things, and none of them is a marketing authorisation. Suppliers cite all three as if they were. We check which one is actually being claimed.

Enforcement Risk, Explained

A plain-language account of FDA’s unapproved new drug authority and the state-level exposure most clinics overlook, organised so your own counsel can assess it. We are not lawyers and this is not a legal opinion.

Statutory Criteria, Substance by Substance

The two frameworks are not the same, and we apply each on its own terms. Section 503A turns on an applicable USP or NF monograph, a component of an FDA-approved drug product, or the 503A Bulks List. Section 503B turns on the 503B Bulks List, or on the compounded drug appearing on FDA’s shortage list at the time it is compounded, distributed and dispensed. We apply those criteria to the particular substance, salt form, formulation and intended use rather than to a product name — FDA has evaluated free base and acetate forms separately in its own briefing materials, and so do we.

Pharmacy Partner Network

For substances with a lawful pathway, we run credential and documentation checks on pharmacy partners — state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities operating under CGMP requirements — and review them per product and per jurisdiction. A facility’s 503B registration is not by itself evidence that a particular compounded drug satisfies every applicable 503B requirement; product-specific eligibility has to be established separately.

Ongoing Monitoring

FDA has flagged both substances as posing potential safety risks in compounding, and that position can move. We track that page, the nominations list, both Bulks Lists, advisory committee agendas and Federal Register notices, and re-date this page when anything changes.

Critical Note for this Category

As of August 2026 neither Thymosin Alpha-1 nor Epitalon appears on the FDA 503A or 503B Bulks List. On the FDA materials we reviewed in August 2026 we did not identify an applicable federal compounding basis for either substance. Because neither substance qualifies, our network does not source them. Licensed practitioners may review our regulatory analysis to evaluate compliance exposure. We provide regulatory information and documentation support only. Clinics exploring them must work with qualified legal counsel to assess compliance risk.

Clinic Benefits

What a practice working in this category actually gets from us.

✓ Credetials Decoded

A clear answer on what a foreign approval, an orphan designation or a committee vote does and does not permit in the United States.

✓ Evidence Separated From Status

How much clinical evidence exists for a substance, stated separately from whether it may lawfully be compounded. In this category the two point in opposite directions.

✓ Claim Discipline

Longevity and anti-ageing are marketing categories, not indications. We flag where protocol descriptions cross from what was studied into what is claimed.

✓ Documentation Support

Help building a compliance file that records what you verified, when, and against which source.

✓ Supplier Vetting

For substances with a lawful pathway, we assess suppliers on regulatory credentials and statutory authority. Where we identify no basis for a substance, no credential cures that, and we say so.

✓ Counsel Ready

The position organised so your attorney can assess it quickly rather than rebuilding the research.

Immune Function and the Biology of Ageing

Immune change with age is a documented research area. Thymic involution, shifts in T-cell populations and chronic low-grade inflammation are all described in the literature and are legitimate subjects of clinical interest. Clinics field questions about them, and practitioners in functional and integrative settings field those questions regularly.

Peptide approaches in this space rest largely on mechanism-level reasoning rather than outcome data in the populations clinics actually treat. That interest sits within prescriber discretion and clinical judgment — which is a separate question from whether the material can lawfully be obtained at all.

The Two Substances in This Category

What it is: A 28-amino-acid peptide originally isolated from thymic tissue. Its generic name is thymalfasin; outside the United States it is marketed as Zadaxin.

Research context: This is the unusual case in the category, because the evidence base is substantial by peptide standards. At the time we checked in August 2026, registry records indicated roughly sixty-five studies, including Phase 4 work in hepatitis B cirrhosis, acute necrotising pancreatitis and HBV-related hepatocellular carcinoma, several enrolling hundreds of patients. Per SciClone Pharmaceuticals’ SEC filings, Zadaxin is approved for sale in more than thirty countries, primarily in Asia, the Middle East and Latin America. Registry and filing details change, so verify both directly rather than relying on this summary.

FDA position: Ta1 holds no FDA approval in the United States. It carries orphan drug designation for chronic active hepatitis B, which was never converted into a marketing authorisation. Orphan-drug designation does not itself constitute FDA approval or authorisation to market a drug. It went before the Pharmacy Compounding Advisory Committee on 4 December 2024, and FDA’s briefing document states plainly that “FDA is proposing that Thymosin alpha-1 (free base) NOT be included on the 503A Bulks List”, with the same proposal for the acetate form. Reporting indicates the committee did not recommend inclusion.

FDA has placed Ta1 on its list of bulk substances that may present significant safety risks in compounding, recording that compounded drugs containing it “may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization.” It appears on neither the 503A nor the 503B Bulks List. We searched for an FDA-approved US drug product containing it, and for an applicable USP or NF monograph, and found neither.

What it is: A tetrapeptide, alanine-glutamate-aspartate-glycine, developed in Russian gerontology research as a synthetic successor to the pineal extract epithalamin. Also written Epithalon; Epitalon is the standard chemical name.

Research context: The literature is largely preclinical and largely Russian-language, running to roughly two hundred records across the major databases. Registry searches return no registered clinical studies. There is no published human trial record for this substance in any indication, and that absence is the central fact about it.

FDA position: Epitalon holds no FDA approval. FDA has flagged it on that same safety list, recording that compounded drugs containing it “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities.”

On 24 July 2026 the Pharmacy Compounding Advisory Committee considered Epitalon for the 503A Bulks List. The nominated use was insomnia, not ageing. FDA’s reviewers recommended against inclusion, noting there are no publications discussing the efficacy of epitalon administered in patients with insomnia. Trade press covering the meeting reported the committee recommending it anyway, by a narrow margin. That vote is advisory. The committee’s recommendation does not itself add a substance to the 503A Bulks List; FDA adds a substance by notice-and-comment rulemaking, and no such rulemaking has followed.

Epitalon appears on neither Bulks List. We searched for an FDA-approved drug product containing it, and for an applicable USP or NF monograph, and found neither.

Regulatory status current as of August 2026

Neither substance appears on either Bulks List, and we did not identify an applicable federal compounding basis for either. Compounding from a bulk drug substance is closed by default and opens only when a statutory condition is met, and on the sources we reviewed none is met here. FDA has flagged both as potential safety risks in compounding. Clinics must verify current FDA and state requirements before any sourcing decision.

The Evidence Does Not Track the Regulatory Outcome

This category contains a contrast worth understanding before any sourcing conversation, because it disproves the assumption most clinics bring to it.

Thymosin Alpha-1 has roughly sixty-five registered trials, Phase 4 studies enrolling hundreds of patients, orphan designation, and approval in more than thirty countries. FDA proposed against adding it to the 503A Bulks List.

Epitalon has no registered trials in any indication, and was nominated for a use its published literature does not address. FDA recommended against it too. The committee recommended it anyway.

The substance with the deeper evidence base was not recommended for inclusion; the one with no registered trial record was. The comparison establishes something a clinic needs to hold onto: evidence and regulatory standing are separate questions, and neither substitutes for the other. A substance does not become compoundable because the science looks good, and it does not become uncompoundable because the science looks thin. What decides the answer is whether the substance satisfies a statutory condition. Neither of these does.

Two things follow, and both come up in supplier conversations:

Approval abroad confers nothing here. Zadaxin’s approvals in Asia, the Middle East and Latin America do not create a US pathway and satisfy no 503A or 503B condition.
Orphan designation is not approval. Ta1’s designation for chronic active hepatitis B has never become a marketing authorisation. Designation is a development incentive, not permission to market or compound.

Licensed prescribers working with these substances operate in a domain of clinical discretion rather than evidence-based protocol. The decision to use, dose and monitor remains the prescriber’s responsibility under the standard of care in their jurisdiction.

Why Clinics Have Explored These Peptides

Despite the regulatory position set out above, both substances have gained attention in clinic settings because:

Ta1’s clinical record is real. Sixty-five registered trials and Phase 4 work in liver disease is substantial by peptide standards, and practitioners who read the literature notice that.
Approval elsewhere reads as validation. A product marketed in thirty-plus countries feels established, even though that status has no bearing on what a US pharmacy may compound.
Off-label prescribing is familiar territory. Practitioners are used to broad discretion in prescribing approved drugs off-label. That discretion does not extend to obtaining a substance no pharmacy may lawfully compound. The two questions are commonly, and incorrectly, treated as one.
Immune and ageing questions persist. Clinics field these questions regularly, and the market has grown around them. Market interest is not evidence of a compounding pathway.

None of the above is a recommendation to use these compounds. We decline to coordinate anything without a lawful pathway, and this page exists so a clinic can see the whole position and hand it to counsel before a supplier quotes a price.

Three Questions Specific to This Category

Our regulatory overview sets out the general supplier checks that apply to every peptide: statutory criteria, pharmacy credentials, research-use-only labelling and documentation. Three questions matter here that do not arise elsewhere.

Which approval is the supplier actually citing?

If a quote for Thymosin Alpha-1 leads with international approval, orphan designation, or the number of published trials, none of those answers the question you asked. Ask which statutory condition the substance satisfies in the United States, and ask for the document. A supplier who answers with Zadaxin’s overseas registrations has changed the subject.

Which salt form, and which route?

FDA evaluates free base and acetate forms as separate substances, and its assessments address specific routes of administration. A quote that names neither is incomplete, and the safety concerns FDA has recorded for both substances are route-dependent.

What is the nominated use being relied on?

Epitalon was assessed for insomnia. Ta1 was assessed against a set of infectious and oncology indications. Neither was assessed for ageing or immune support in healthy adults. If a supplier points to FDA’s evaluation as evidence of anything, ask which indication was evaluated — the answer will rarely be the one the clinic has in mind.

Availability Through Phoenix Meds

Sourcing Position (August 2026)

As of August 2026, neither substance appears on the 503A Bulks List, and we have not identified a lawful federal compounding pathway that would permit us to coordinate their sourcing. Therefore, we put that finding in front of the clinic before an order, and we re-check it when the record moves.

Our approach is narrower: we establish the current position of a substance and its salt form, test a supplier’s stated legal basis against the primary record, distinguish foreign approval and orphan designation from US compounding authority, and help build the compliance file that documents it. Where a preparation does have a lawful pathway, we coordinate sourcing through licensed partners in the ordinary way. Licensed practitioners can request a regulatory status review for any substance in this category.

We maintain this page because clinics are being told otherwise. If a supplier has quoted you either substance on the strength of the July 2026 committee vote, or on Zadaxin’s overseas approvals, that is worth knowing before you order rather than after.

If FDA opens a rulemaking or alters the nominations list in a way that affects either substance, we will update this page and re-date it.

Verify This Yourself

FDA briefing document — Thymosin Alpha-1, PCAC December 2024 — the agency’s proposal against inclusion, for both the free base and the acetate

FDA — Certain Bulk Drug Substances That May Present Significant Safety Risks — FDA’s recorded safety concerns for both substances, quoted on this page. Content current 22 April 2026 when we checked.

21 CFR 216.23 — the 503A Bulks List as codified. Six substances when we checked in August 2026, no peptides among them; FDA adds to this list by rulemaking, so check the current text rather than relying on that count.

FDA — PCAC meeting, 23–24 July 2026 — the Epitalon review and its nominated use

FDA — PCAC meeting, 4 December 2024 — the Thymosin Alpha-1 review

FDA — 503B Bulk Drug Substances List — the substances FDA has determined may be used by outsourcing facilities under section 503B. Five substances when we checked in August 2026, no peptides among them; FDA updates this list, so check it rather than relying on that count.

Disclaimer & Legal Status

This page is educational and regulatory-tracking information for licensed clinics. It is not medical or legal advice. For the statutory framework, enforcement risk, research-use-only labelling and required due diligence, see our Legal & Regulatory Status Overview, and work with qualified legal counsel in your state.

Status, August 2026

Neither Thymosin Alpha-1 nor Epitalon appears on the FDA 503A or 503B Bulks List. Based on the FDA materials Phoenix Meds reviewed in August 2026, we did not identify an applicable federal compounding basis for either substance, and we do not coordinate their sourcing. FDA has flagged both as potential safety risks in compounding. Ageing is not an indication FDA recognises, and neither substance has been evaluated by FDA for such a use — clinics should not describe protocols in this category as anti-ageing or longevity treatments.

Phoenix Meds does not coordinate sourcing of Thymosin Alpha-1 or Epitalon, as single agents or as components of a blend. We are not physicians, pharmacists or legal counsel, and nothing here is an offer to source these substances.